Haemacure completes trial of Hemaseel:
This article was originally published in Clinica
Haemacure's Hemaseel has shown no significant side-effects in a Phase I human trial. The study investigated the safety of a single dose of the fibrin sealant applied topically to a small incision on the forearm of ten volunteers. Haemacure, which is based in Montreal, Canada, conducted the study of its sealant intended to control bleeding in orthopaedic and general surgery at the Chelsea and Westminster Hospital in London, UK.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.